These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 8287511)
1. Which patients need aggressive lipid-altering therapy? Hunninghake DB Cleve Clin J Med; 1993; 60(6):483-4. PubMed ID: 8287511 [No Abstract] [Full Text] [Related]
2. Choice of lipid-regulating drugs. Med Lett Drugs Ther; 2001 May; 43(1105):43-8. PubMed ID: 11378632 [No Abstract] [Full Text] [Related]
3. [Gemfibrozil in the differential therapy of disorders of fat metabolism]. Ebner F Fortschr Med; 1992 Oct; 110(28):523-6. PubMed ID: 1398412 [TBL] [Abstract][Full Text] [Related]
4. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Boden WE; Pearson TA Am J Cardiol; 2000 Mar; 85(5):645-50, A10. PubMed ID: 11078282 [TBL] [Abstract][Full Text] [Related]
5. [Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?]. März W MMW Fortschr Med; 2005 Apr; 147(14):14. PubMed ID: 15887675 [No Abstract] [Full Text] [Related]
7. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Smit JW; Jansen GH; de Bruin TW; Erkelens DW Am J Cardiol; 1995 Jul; 76(2):126A-128A. PubMed ID: 7604787 [TBL] [Abstract][Full Text] [Related]
8. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy. Duvall WL; Blazing MA; Saxena S; Guyton JR J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203 [TBL] [Abstract][Full Text] [Related]
9. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. Sprecher DL Am J Cardiol; 2000 Dec; 86(12A):46L-50L. PubMed ID: 11374856 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310 [TBL] [Abstract][Full Text] [Related]
12. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Whitney EJ; Krasuski RA; Personius BE; Michalek JE; Maranian AM; Kolasa MW; Monick E; Brown BG; Gotto AM Ann Intern Med; 2005 Jan; 142(2):95-104. PubMed ID: 15657157 [TBL] [Abstract][Full Text] [Related]
13. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Alagona P Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of HMG-CoA reductase in mononuclear cells during gemfibrozil treatment. Stange EF; Osenbrügge M; Rustan M; Reimann F; Schneider A; Ditschuneit HH; Ditschuneit H Atherosclerosis; 1991 Dec; 91(3):257-65. PubMed ID: 1789808 [TBL] [Abstract][Full Text] [Related]
15. Drug therapy of hyperlipidemia. Prihoda JS; Illingworth DR Curr Probl Cardiol; 1992 Sep; 17(9):545-605. PubMed ID: 1446461 [No Abstract] [Full Text] [Related]
16. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins. Nakandakare E; Garcia RC; Rocha JC; Sperotto G; Oliveira HC; Quintão EC Atherosclerosis; 1990 Dec; 85(2-3):211-7. PubMed ID: 2102085 [TBL] [Abstract][Full Text] [Related]